GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Athenex Inc (OTCPK:ATNXQ) » Definitions » Goodwill

Athenex (Athenex) Goodwill : $0.0 Mil (As of Dec. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Athenex Goodwill?

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Athenex's goodwill for the quarter that ended in Dec. 2022 was $0.0 Mil.


Athenex Goodwill Historical Data

The historical data trend for Athenex's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athenex Goodwill Chart

Athenex Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Goodwill
Get a 7-Day Free Trial 37.50 38.51 38.89 - -

Athenex Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Goodwill Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Athenex Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.


Athenex  (OTCPK:ATNXQ) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Athenex's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Goodwill-to-Asset (A: Dec. 2022 )=Goodwill/Total Assets
=0/204.055
=0.00

Athenex's Goodwill-to-Asset Ratio for the quarter that ended in Dec. 2022 is calculated as

Goodwill-to-Asset (Q: Dec. 2022 )=Goodwill/Total Assets
=0/204.055
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Athenex Goodwill Related Terms

Thank you for viewing the detailed overview of Athenex's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.


Athenex (Athenex) Business Description

Traded in Other Exchanges
N/A
Address
1001 Main Street, Suite 600, Conventus Building, Buffalo, NY, USA, 14203
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.
Executives
Jinn Wu director 107 MORGAN LANE, PLAINSBORO NJ 08536
Lau Johnson Yiu Nam director, officer: CEO and Chairman of the Board
Joe Annoni officer: Chief Financial Officer C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Timothy Devere Cook officer: See Remarks C/O ATHENEX, INC., 1001 MAIN STREET,, SUITE 600, BUFFALO NY 14203
Daniel Lang officer: Pres Cell Therapy, VP Corp Dev C/O ATHENEX, INC. CONVENTUS BUILDING, 1001 MAIN ST. STE. 600, BUFFALO NY 14203
Jordan Kanfer director C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Rudolf Kwan director, officer: EVP, Chief Medical Officer C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Michael Smolinski officer: Chief Scientific Officer C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Steven J. Adams officer: Interim Chief Acct Officer C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Kim Campbell director 3300 HYLAND AVE, COSTA MESA CA 92626
William Wei Zuo officer: President, China 3040 POST OAK BLVD, SUITE 1110, HOUSTON TX 77056
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Manson Fok director C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Randoll Sze officer: Chief Financial Officer C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Stephanie A Davis director C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203